Stem Cell Therapeutics Corp. (SCT) has entered into an option agreement to exclusively license worldwide rights to a series of prostate cancer stem cell assets from the University of York, UK. The assets originate from Yorkshire Cancer Research (YCR) under the direction of Professor Norman Maitland. SCT plans to work with the Maitland group, leveraging SCT’s scientific expertise and its global network of collaborators. The license agreement will contain customary terms and provisions for assets at this stage of development, including an initial license consideration, milestone payments, royalties on sales and sublicensing terms.
"This agreement provides Stem Cell Therapeutics with an opportunity to evaluate several highly promising therapeutic targets, all of which are expressed on prostate cancer stem cells, as well as on other types of cancers," said Dr. Bob Uger, SCT's chief scientific officer. "Much of the York group's research is focused on hypothesis testing using powerful multicellular in vitro models and xenograft in vivo models of tumor development/metastasis. We will extend this research into the generation of monoclonal antibodies to these targets, with an ultimate goal of identifying new therapeutic development candidates."